Clonidine
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | KAPVAY | — | 2010-09-28 – 2014-11-20 | fda.gov ↗ |
| Label expansion | US (FDA) | CATAPRES | — | 1979-09-20 | fda.gov ↗ |
| Approved | US (FDA) | CATAPRES | — | 1974-09-03 | fda.gov ↗ |
Trials 151 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT04423627 | Jun 2021 → Jul 2025 | hypertensive disorder | University of Iowa | Completed | No outcome recorded |
| Phase 0 | NCT04737512 | Feb 2021 → Oct 2024 | attention deficit-hyperactivity disorder | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT04263064 | Mar 2020 → Aug 2022 | — | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 0 | NCT04030572 | Dec 2019 → Mar 2020 | cancer, neurodegenerative disease | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 0 | NCT04032691 | Aug 2019 → May 2021 | — | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 0 | NCT05037812 | Mar 2019 → Mar 2028 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03147092 | Feb 2018 → Jun 2020 | hypertensive disorder | Centro Neurológico de Pesquisa e Reabiitação, Brazil | Unknown | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT06781632 | Nov 2024 → Feb 2025 | — | PHARMAFINA | Completed | No outcome recorded |
| Phase 1 | NCT05592379 | Nov 2023 → Feb 2025 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT04934228 | Jul 2021 → Aug 2026 overdue | diabetes mellitus, hypertensive disorder, obesity disorder | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05536362 | Feb 2021 → Jan 2022 | colon carcinoma | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT03520543 | May → Jul 2018 | — | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 1 | NCT02249039 | Sep 2015 → Dec 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT02548806 | Sep → Dec 2015 | — | Valerio Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02268448 | Jul 2015 → Sep 2022 | dermatitis | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT01136278 | Jul → Dec 2010 | amphetamine abuse, mood disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT00295308 | Nov 2005 → Jul 2014 | opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00318760 | Jun 2005 → Aug 2013 | cocaine abuse, opioid abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT06447194 | Oct 2025 → Jan 2027 | intervertebral disk degenerative disorder, lumbar spinal stenosis, spondylolisthesis | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01986751 | Jan 2014 → Dec 2015 | — | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 1/2 | NCT01862250 | Oct 2013 → Apr 2015 | brain hypoxia - ischemia | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT00730054 | Feb → May 2005 | — | Oslo University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00194974 | Jul 2004 → Mar 2005 | proteinuria, toxemia of pregnancy | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00262470 | Apr 1997 → Dec 2029 expected | cardiac rhythm disease | Satish R. Raj | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT00166686 | — | cancer-related condition | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 225 trials | ||||||
| Phase 2 | NCT07131657 | Sep → Dec 2025 | — | PHARMAFINA | Completed | No outcome recorded |
| Phase 2 | NCT05487196 | Sep 2022 → Jul 2023 | pregnancy disorder | Grace Lim, MD, MS | Completed | No outcome recorded |
| Phase 2 | NCT05360953 | Jun 2022 → Aug 2025 | post-traumatic stress disorder | Charite University, Berlin, Germany | Suspended | No outcome recorded |
| Phase 2 | NCT05355597 | Jan 2021 → Mar 2025 | musculoskeletal system disorder, soft tissue neoplasm | Atlantic Health System | Terminated | No outcome recorded |
| Phase 2 | NCT02812368 | Aug 2016 → Jan 2017 | autism spectrum disorder | Ohio State University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02643251 | Dec 2015 → Nov 2016 | diabetic neuropathy, neuropathy, painful | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 2 | NCT02444559 | May → Jun 2015 | — | Zealand University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02355158 | Jun 2014 → Aug 2015 | diabetes mellitus, neuropathy, painful | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 2 | NCT01956604 | Apr 2014 → Sep 2017 | delirium | Oslo University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02068027 | Mar 2014 → Mar 2015 | diabetic polyneuropathy | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 2 | NCT01983462 | Oct 2013 → Jun 2020 | hypertensive disorder, obesity disorder | Gary L. Pierce | Terminated | No outcome recorded |
| Phase 2 | NCT01963299 | Aug → Oct 2013 | posterior dislocation of lens | Centre Hospitalier Universitaire Dijon | Completed | No outcome recorded |
| Phase 2 | NCT02733757 | May 2013 → Oct 2015 | — | Federal University of Minas Gerais | Completed | No outcome recorded |
| Phase 2 | NCT01784250 | Aug 2012 → Apr 2013 | anxiety | CES University | Unknown | No outcome recorded |
| Phase 2 | NCT01322048 | Aug 2011 → Jan 2015 | traumatic brain injury | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT01370811 | Aug 2011 → Sep 2012 | — | Orient Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01415895 | Jul 2011 → Feb 2013 | — | Annette C. Toledano MD | Completed | No outcome recorded |
| Phase 2 | NCT01293149 | Apr 2011 → Mar 2013 | — | Nationwide Children's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01297335 | Feb 2011 → Jul 2012 | hypertensive disorder | The Center for Clinical Research, Winston-Salem, NC | Completed | No outcome recorded |
| Phase 2 | NCT00130091 | Sep 2009 → Feb 2014 | hydrocele | Children's Hospital of Eastern Ontario | Completed | No outcome recorded |
| Phase 2 | NCT00930072 | Apr 2009 → Dec 2014 | intracranial vasospasm | University of Washington | Terminated | No outcome recorded |
| Phase 2 | NCT00884832 | Oct 2008 → Aug 2012 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01638052 | Feb 2006 → Mar 2008 | cholesteatoma, otorhinolaryngologic disease | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00510016 | Jul 2002 → Dec 2005 | neonatal abstinence syndrome | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000279 | Sep 1994 → Aug 1999 | substance-related disorder | Yale University | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT05091242 | Oct 2021 → Jan 2026 | delirium | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 2/3 | NCT04648020 | Feb 2021 → May 2023 | chemotherapy-induced oral mucositis | Monopar Therapeutics | Terminated | No outcome recorded |
| Phase 2/3 | NCT01598896 | May 2012 → Aug 2017 | cannabis dependence | Mclean Hospital | Terminated | No outcome recorded |
| Phase 2/3 | NCT02030717 | Feb 2012 → May 2015 | renal cell carcinoma | Umeå University | Completed | No outcome recorded |
| Phase 2/3 | NCT01360450 | Jul 2011 | neonatal abstinence syndrome | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 323 trials | ||||||
| Phase 3 | NCT01876355 | Jan → Dec 2024 | delirium | Deventer Ziekenhuis | Unknown | No outcome recorded |
| Phase 3 | NCT06137924 | Dec 2023 → Apr 2024 | — | Universidad Simón Bolívar | Unknown | No outcome recorded |
| Phase 3 | NCT04877093 | Jun 2023 → Mar 2027 expected | post-traumatic stress disorder | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT03653832 | Dec 2018 → Dec 2023 | — | University of Edinburgh | Completed | No outcome recorded |
| Phase 3 | NCT03727100 | Oct 2018 → Mar 2020 | radiculopathy | Sollis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03537612 | Jun 2018 → Apr 2022 | scoliosis | Dr. Jean A. Ouellet, MD, FRCSC | Terminated | No outcome recorded |
| Phase 3 | NCT02466373 | Dec 2016 → Apr 2018 | delirium | Deventer Ziekenhuis | Completed | No outcome recorded |
| Phase 3 | NCT02891798 | Oct 2016 → Jul 2021 | — | Brian Williams | Completed | No outcome recorded |
| Phase 3 | NCT02740127 | Jun 2016 → May 2020 | male reproductive organ cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT02509273 | May 2016 → Oct 2018 | — | University of Erlangen-Nürnberg Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02655965 | May 2016 → Nov 2019 | — | Jules Bordet Institute | Completed | No outcome recorded |
| Phase 3 | NCT02592915 | Oct 2015 → Dec 2022 | — | Queen Fabiola Children's University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02181543 | Aug 2013 → Dec 2014 | — | Professor Fernando Figueira Integral Medicine Institute | Completed | No outcome recorded |
| Phase 3 | NCT02371759 | Jun 2013 → Jan 2016 | diabetes mellitus | University of Belgrade | Completed | No outcome recorded |
| Phase 3 | NCT01559012 | Feb → Dec 2012 | hyperemesis gravidarum | A.O.U. Città della Salute e della Scienza | Completed | No outcome recorded |
| Phase 3 | NCT01082874 | Jul 2010 → Mar 2014 | cardiovascular disorder | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00678379 | Apr 2008 → Nov 2009 | — | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00661063 | Apr 2008 → Apr 2009 | diabetic neuropathy | Irmandade da Santa Casa de Misericordia de Sao Paulo | Unknown | No outcome recorded |
| Phase 3 | NCT00723190 | Jan 2008 → Mar 2010 | attention deficit-hyperactivity disorder | Shionogi | Completed | No outcome recorded |
| Phase 3 | NCT00417443 | Dec 2007 → Dec 2009 | — | Cambridge University Hospitals NHS Foundation Trust | Withdrawn | No outcome recorded |
| Phase 3 | NCT00556959 | Oct 2007 → Aug 2008 | attention deficit-hyperactivity disorder | Addrenex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00437996 | Feb 2007 → Jan 2008 | — | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 3 | NCT00287326 | Jan → Jun 2006 | — | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 452 trials | ||||||
| Phase 4 | NCT07567495 | Jun 2026 → May 2028 expected | — | Columbia University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07313371 | Jan → Jul 2026 overdue | substance dependence | University of Sao Paulo General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05416840 | Jan 2024 → Nov 2026 expected | hypertensive disorder | Jing Liu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05848531 | Apr → Dec 2023 | sickle cell disease | Centre Hospitalier Universitaire Saint Pierre | Unknown | No outcome recorded |
| Phase 4 | NCT05676814 | Mar → Jun 2023 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT05824832 | Feb 2023 → Jun 2026 overdue | neuropathy, painful | Loyola University | Recruiting | No outcome recorded |
| Phase 4 | NCT05575219 | Oct 2022 → Feb 2024 | substance withdrawal syndrome | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT05560230 | Oct 2022 → Aug 2024 | endometriosis | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT04902859 | Apr 2022 → Dec 2024 | retinopathy of prematurity | Region Örebro County | Unknown | No outcome recorded |
| Phase 4 | NCT05029726 | Feb 2022 → Feb 2027 expected | ganglion or cyst of synovium/tendon/bursa, intervertebral disk degenerative disorder, lumbar disk disease, lumbar spinal stenosis +3 | John O'Toole | Recruiting | No outcome recorded |
| Phase 4 | NCT05029050 | Jan 2022 → Jul 2024 | delirium, subjective cognitive decline | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04186299 | Aug 2021 → Aug 2022 | pulpitis | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 4 | NCT04828226 | Apr 2021 → May 2026 | bipolar disorder, catatonia, delirium, major depressive disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 4 | NCT04564430 | Mar → Dec 2021 | arthropathy, clubfoot, congenital deformities of limbs, exostosis, Dupuytren subungual +8 | Odense University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04758936 | Feb 2021 → Feb 2022 | delirium | Erasme University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04530903 | Sep 2020 → Jan 2021 | — | Centre Hospitalier Universitaire Saint Pierre | Unknown | No outcome recorded |
| Phase 4 | NCT03696199 | Sep 2020 → Sep 2026 expected | — | Lahey Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT04026074 | Jul → Oct 2019 | arthropathy | Medical University of Graz | Completed | No outcome recorded |
| Phase 4 | NCT03092011 | Feb 2018 → Oct 2024 overdue | neonatal abstinence syndrome | The Cooper Health System | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03057015 | May 2017 → Feb 2019 | — | University of Vermont | Unknown | No outcome recorded |
| Phase 4 | NCT03121261 | May 2017 → Sep 2027 expected | — | University Hospital Dubrava | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03109795 | Apr 2017 → Jun 2023 | anxiety, hypertensive disorder | University of Iowa | Terminated | No outcome recorded |
| Phase 4 | NCT03124082 | Jan → Dec 2017 | — | University of Parma | Unknown | No outcome recorded |
| Phase 4 | NCT03018171 | Jan → Jun 2017 | — | San Giovanni Calibita Fatebenefratelli Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02953210 | Nov 2016 | neuropathy, painful, paralytic ileus | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT02778178 | May 2016 → Apr 2017 | — | University Hospital, Lille | Completed | No outcome recorded |
| Phase 4 | NCT02530151 | Nov 2015 → May 2017 | — | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT02571283 | Oct 2015 → May 2016 | — | University of Louisville | Withdrawn | No outcome recorded |
| Phase 4 | NCT02570503 | Oct 2015 → Feb 2021 | osteoarthritis, knee | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 4 | NCT02365727 | Apr → Aug 2015 | osteoarthritis, knee | The Hawkins Foundation | Withdrawn | No outcome recorded |
| Phase 4 | NCT02361476 | Jan → Dec 2015 | drug-induced akathisia | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT01846221 | Jul 2014 → Jan 2017 | — | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT02026687 | Mar 2014 → Apr 2016 | female reproductive organ cancer | Lena Nilsson | Completed | No outcome recorded |
| Phase 4 | NCT02067078 | Feb → Dec 2014 | — | Regionshospitalet Silkeborg | Completed | No outcome recorded |
| Phase 4 | NCT03117140 | Dec 2013 → Mar 2017 | — | Melinda Seering | Completed | No outcome recorded |
| Phase 4 | NCT01785693 | Jan 2013 → Nov 2016 | peripheral arterial occlusive disease 1 | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT01902108 | Jan 2013 → Dec 2015 | — | St Joseph University, Beirut, Lebanon | Completed | No outcome recorded |
| Phase 4 | NCT01761916 | Jan → Jun 2013 | preeclampsia | Instituto Materno Infantil Prof. Fernando Figueira | Completed | No outcome recorded |
| Phase 4 | NCT03065933 | Jan 2012 → Jan 2013 | manic bipolar affective disorder | Mclean Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01759524 | Oct 2011 → Jan 2013 | — | Cork University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01139996 | May 2010 → Aug 2012 | delirium | Memorial Health University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT00959062 | Jan 2010 → Sep 2012 | — | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01052623 | Jan 2010 → Dec 2011 | ataxia telangiectasia | Johann Wolfgang Goethe University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00983125 | Aug 2009 → Mar 2010 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT00860925 | May → Dec 2009 | cardiovascular disorder | McMaster University | Completed | No outcome recorded |
| Phase 4 | NCT00858845 | May 2008 → Mar 2011 | heart failure | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00152750 | Sep 2006 → Oct 2008 | Tourette syndrome, attention deficit-hyperactivity disorder | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT00335582 | Jun 2006 → Aug 2009 | heart disorder | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT00535925 | Oct 2005 → Dec 2011 | diabetic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00279253 | Mar 2004 → Jan 2005 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00312416 | Feb → Dec 2004 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00691795 | ? → Dec 2011 | — | Columbia University | Withdrawn | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT06780865 | Jan 2025 → Dec 2028 expected | chronic kidney disease, secondary hypertension | Shanghai Institute of Hypertension | Not yet recruiting | No outcome recorded |
| — | NCT06507410 | Jul → Sep 2024 overdue | — | Tanta University | Recruiting | No outcome recorded |
| — | NCT05485480 | Nov 2022 → Feb 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT05318248 | Mar 2022 → Mar 2023 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT02539693 | Oct 2016 → Apr 2022 | pilonidal sinus | Makassed General Hospital | Unknown | No outcome recorded |
| — | NCT02439281 | May 2015 → May 2018 | — | Mihaela Visoiu | Terminated | No outcome recorded |
| — | NCT02550444 | Apr → May 2015 | pregnancy disorder | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT02355678 | Jan → Aug 2015 | — | Makassed General Hospital | Completed | No outcome recorded |
| — | NCT02239627 | Sep 2014 → Jun 2015 | — | West Virginia University | Terminated | No outcome recorded |
| — | NCT02541071 | Nov 2013 → Oct 2014 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT01813149 | Aug 2012 → Jun 2016 | complex regional pain syndrome | The Cleveland Clinic | Terminated | No outcome recorded |
| — | NCT01205204 | Aug 2010 → Jul 2011 | — | Pravara Institute of Medical Sciences University | Withdrawn | No outcome recorded |
| — | NCT01175668 | Jul 2010 → Aug 2012 | neonatal abstinence syndrome | Baystate Medical Center | Terminated | No outcome recorded |
| — | NCT01507701 | Jan → Mar 2010 | myalgic encephalomeyelitis/chronic fatigue syndrome | Oslo University Hospital | Completed | No outcome recorded |
| — | NCT05831761 | Sep 2009 → Oct 2011 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT00588354 | Oct 2006 → Feb 2009 | radiculopathy | Mayo Clinic | Terminated | No outcome recorded |
| — | NCT00585871 | May 2006 → Jan 2012 | ventricular tachycardia | James Martins | Withdrawn | No outcome recorded |
| — | NCT00206986 | May 2005 → Dec 2011 | schizophrenia | Birte Glenthoj | Completed | No outcome recorded |
| — | NCT00580151 | Jun 2004 → Jun 2014 | anxiety | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| — | NCT00356226 | Oct 2000 → ? | cirrhosis of liver | CHU de Charleroi | Completed | No outcome recorded |
Also used as a comparator or background therapy in 100 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04833218 Comparator | Jan 2020 → Jun 2021 | traumatic brain injury | Minia University | Unknown | No outcome recorded |
| Phase 0 | NCT03388814 Background | Nov 2018 → Jun 2020 | breast cancer, neuropathy, painful, substance-related disorder | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 0 | NCT02991404 Background | Feb → Nov 2017 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07360301 Background | Sep 2026 → Feb 2028 expected | — | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05943613 Comparator | Dec 2023 → Sep 2025 | — | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT05371574 Comparator | Jan → Aug 2022 | — | Uwakwe Emmanuel Chijioke | Unknown | No outcome recorded |
| Phase 1 | NCT04445337 Background | Nov 2020 → Oct 2021 | COVID-19, acute respiratory distress syndrome | University of Nebraska | Terminated | No outcome recorded |
| Phase 1 | NCT00748059 Background | Dec 1996 → Dec 2020 | autonomic nervous system disorder, disorder of catecholamine synthesis, orthostatic hypotension | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01425658 Comparator | Aug 2011 → Jan 2012 | — | Qazvin University Of Medical Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT01188421 Comparator | Oct 2010 → Jun 2015 | opiate dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT00672347 Comparator | Jul → Sep 2008 | — | Federal University of Minas Gerais | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT06031090 Comparator | Mar → Oct 2023 | benign shuddering attacks | Zagazig University | Unknown | No outcome recorded |
| Phase 2 | NCT04603911 Comparator | Dec 2020 → Apr 2023 | breast cancer | Tufts Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03552068 Comparator | May 2019 → Jul 2021 | Parkinson disease, psychogenic movement disorders | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 2 | NCT03342950 Comparator | Feb 2019 → Oct 2021 | peripheral neuropathy | Terence J. Coderre | Terminated | No outcome recorded |
| Phase 2 | NCT03670160 Comparator | Oct 2018 → May 2020 | neonatal abstinence syndrome | University of Tennessee Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03007966 Background | Jan 2017 → Feb 2018 | hernia, double inguinal | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02769390 Comparator | Jul → Nov 2015 | — | Federal University of Minas Gerais | Completed | No outcome recorded |
| Phase 2 | NCT01530373 Comparator | Feb 2012 → Jul 2027 expected | breast cancer | University of Arkansas | Recruiting | No outcome recorded |
| Phase 2 | NCT01677351 Comparator | Jul 2011 → Sep 2012 | cardiac rhythm disease | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2 | NCT01385748 Comparator | Apr 2010 → Oct 2014 | chemotherapy-induced oral mucositis | Valerio Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01040429 Comparator | Feb 2010 → Jun 2012 | myalgic encephalomeyelitis/chronic fatigue syndrome | Oslo University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01597427 Comparator | Mar 2009 → Apr 2011 | — | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT01620112 Comparator | Feb 2009 → Jul 2011 | — | Federal University of Rio de Janeiro | Completed | No outcome recorded |
| Phase 2 | NCT00695565 Comparator | May 2008 → Dec 2009 | diabetic polyneuropathy | Arcion Therapeutics Inc | Completed | No outcome recorded |
| Phase 2 | NCT00350532 Comparator | Sep 2004 → Mar 2008 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00349921 Comparator | Aug 2004 → Jan 2008 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00414921 Comparator | Sep 2003 → Jun 2007 | attention deficit-hyperactivity disorder | University of Cincinnati | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07151417 Background | Sep 2025 → Aug 2026 overdue | osteoarthritis, knee | Walter Reed National Military Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07062497 Comparator | Jan → Dec 2025 overdue | abdominal wall malformation | Federal University of Rio de Janeiro | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03155646 Comparator | Jun 2017 → Aug 2019 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02543944 Comparator | Feb 2016 → May 2021 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 2/3 | NCT01856517 Comparator | Aug 2013 | infectious disease with sepsis | Central Directorate of the Army Health Service | Terminated | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT07092566 Comparator | Nov 2025 → Oct 2027 expected | renal carcinoma | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT05614648 Comparator | Jun 2023 → Mar 2024 | radiculopathy | Sollis Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT04797312 Background | Jul 2021 → Nov 2022 | local anesthetic poisoning | University Hospital, Angers | Unknown | No outcome recorded |
| Phase 3 | NCT03725930 Comparator | Mar 2019 → Nov 2021 | — | University Hospital, Lille | Completed | No outcome recorded |
| Phase 3 | NCT03396588 Comparator | Dec 2017 → Apr 2024 | neonatal abstinence syndrome | Henrietta Bada | Completed | No outcome recorded |
| Phase 3 | NCT02741713 Comparator | Apr 2016 → Jun 2017 | bicipital tenosynovitis | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02563821 Comparator | Nov 2015 → Dec 2018 | — | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 3 | NCT02628626 Comparator | Nov 2015 → Apr 2022 | malabsorption syndrome | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT02324413 Comparator | Oct 2013 → Mar 2014 | — | Richard Beringer | Completed | No outcome recorded |
| Phase 3 | NCT00031395 Comparator | Sep 1999 → Jun 2007 | attention deficit-hyperactivity disorder | University of Cincinnati | Completed | No outcome recorded |
| Phase 432 trials | ||||||
| Phase 4 | NCT07097493 Comparator | Aug → Dec 2026 expected | osteoarthritis, knee | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07350252 Comparator | Mar 2026 → Mar 2027 expected | osteoarthritis, knee | Region Skane | Recruiting | No outcome recorded |
| Phase 4 | NCT07377630 Comparator | Mar 2026 → Mar 2027 expected | pregnancy disorder | Gaslini Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07256938 Comparator | Dec 2025 → Dec 2026 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06935331 Background | Oct 2025 → Dec 2026 expected | adolescent idiopathic scoliosis | OrthoCarolina Research Institute, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07044609 Comparator | Jul 2025 → Dec 2026 expected | attention deficit-hyperactivity disorder, oppositional defiant disorder | Las Vegas Medical Research, LLC DBA Vector Clinical Trials | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05916339 Comparator | Oct 2023 → Jan 2027 expected | attention deficit-hyperactivity disorder, autism spectrum disorder | Daniel Coury | Recruiting | No outcome recorded |
| Phase 4 | NCT05172739 Comparator | Oct 2021 → Nov 2025 overdue | chronic pain syndrome, non-small cell lung carcinoma, substance-related disorder | University of Crete | Recruiting | No outcome recorded |
| Phase 4 | NCT04894864 Comparator | Oct 2020 → Sep 2026 expected | abdominal aortic aneurysm | University of Crete | Recruiting | No outcome recorded |
| Phase 4 | NCT03845894 Comparator | Mar 2020 → Jun 2022 | — | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 4 | NCT03762317 Comparator | Apr → Dec 2018 | neonatal abstinence syndrome | Hennepin County Medical Center, Minneapolis | Terminated | No outcome recorded |
| Phase 4 | NCT03679052 Comparator | Mar → Aug 2018 | benign shuddering attacks | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03119038 Comparator | Apr 2016 → Oct 2022 | osteoarthritis | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT03704376 Comparator | Feb 2016 → Nov 2017 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT02543801 Comparator | Jan 2016 → Aug 2018 | — | Kootenai Health | Completed | No outcome recorded |
| Phase 4 | NCT01112878 Comparator | Jun 2015 | — | Cedars-Sinai Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT02365961 Background | Apr 2015 → Jun 2017 | developmental dysplasia of the hip | The Hawkins Foundation | Completed | No outcome recorded |
| Phase 4 | NCT02128451 Comparator | Apr → Oct 2014 | — | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT03017430 Comparator | Jan 2014 → Dec 2019 | substance withdrawal syndrome | St. Petersburg Bekhterev Research Psychoneurological Institute | Completed | No outcome recorded |
| Phase 4 | NCT02682498 Comparator | Oct 2013 → Jul 2015 | osteoarthritis, knee | University of California, Irvine | Completed | No outcome recorded |
| Phase 4 | NCT03174067 Comparator | Mar 2013 → Apr 2016 | opiate dependence, substance withdrawal syndrome | St. Joseph's Health Centre Toronto | Completed | No outcome recorded |
| Phase 4 | NCT01643434 Comparator | Aug 2012 → Dec 2013 | hypertensive disorder | Instituto do Coracao | Unknown | No outcome recorded |
| Phase 4 | NCT01734551 Comparator | Sep 2011 → Dec 2014 | neonatal abstinence syndrome | Henrietta Bada | Completed | No outcome recorded |
| Phase 4 | NCT01439126 Comparator | Aug 2011 → Oct 2012 | attention deficit-hyperactivity disorder | Concordia Pharmaceuticals Inc., Barbados | Completed | No outcome recorded |
| Phase 4 | NCT02773602 Comparator | May 2011 → Dec 2016 | — | The University of Texas Health Science Center, Houston | Unknown | No outcome recorded |
| Phase 4 | NCT01619436 Comparator | Jan 2011 → Jan 2012 | — | Federal University of Juiz de Fora | Completed | No outcome recorded |
| Phase 4 | NCT00860899 Comparator | Dec 2007 → Oct 2008 | — | University Hospital Dubrava | Completed | No outcome recorded |
| Phase 4 | NCT00370838 Comparator | Feb 2007 → Jul 2008 | Tourette syndrome | Harvey S. Singer | Completed | No outcome recorded |
| Phase 4 | NCT01075490 Comparator | Nov 2006 | — | University Hospital, Montpellier | Unknown | No outcome recorded |
| Phase 4 | NCT00661895 Background | Aug 2005 → Aug 2009 | hypertensive disorder | Creighton University | Completed | No outcome recorded |
| Phase 4 | NCT00421863 Background | Feb 2005 → Jan 2009 | hypertensive disorder | Heart Care Foundation | Completed | No outcome recorded |
| Phase 4 | NCT02177461 Background | Apr 2000 → Aug 2002 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable25 trials | ||||||
| — | NCT07461376 Comparator | Apr 2025 → Jun 2026 overdue | — | Cairo University | Recruiting | No outcome recorded |
| — | NCT06230081 Comparator | Feb 2024 → Mar 2025 overdue | osteoarthritis | Region Skane | Active not recruiting | No outcome recorded |
| — | NCT06180941 Comparator | Dec 2023 → Jun 2024 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT05790044 Comparator | Oct 2023 → Oct 2024 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT06287151 Comparator | Aug 2023 → Feb 2025 | — | Nationwide Children's Hospital | Completed | No outcome recorded |
| — | NCT07297888 Comparator | Jul 2022 → Jan 2024 | — | Shri Guru Ram Rai Institute of Medical and Health Sciences | Completed | No outcome recorded |
| — | NCT04538573 Comparator | May 2022 → Aug 2023 | — | St. Justine's Hospital | Unknown | No outcome recorded |
| — | NCT04436250 Background | Oct 2020 → Aug 2024 | fibromyalgia | Grand Hôpital de Charleroi | Terminated | No outcome recorded |
| — | NCT03770013 Comparator | Jan 2019 → Jun 2020 | — | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT03477994 Comparator | Dec 2018 → Feb 2019 | delirium | Ain Shams University | Completed | No outcome recorded |
| — | NCT02643355 Comparator | Nov 2015 → Jun 2017 | substance withdrawal syndrome | Hennepin Healthcare Research Institute | Completed | No outcome recorded |
| — | NCT02545530 Comparator | May 2015 → May 2016 | — | Peking University People's Hospital | Unknown | No outcome recorded |
| — | NCT02276495 Background | Jan 2015 → Jun 2020 | — | University of California, Irvine | Completed | No outcome recorded |
| — | NCT02362256 Background | May → Jun 2014 | opiate dependence | Vilnius University | Completed | No outcome recorded |
| — | NCT02410460 Background | Sep 2013 → Jun 2014 | — | Mercy Facial Plastic Surgery Center | Completed | No outcome recorded |
| — | NCT01851486 Comparator | Jan 2013 → Sep 2016 | — | Rambam Health Care Campus | Withdrawn | No outcome recorded |
| — | NCT01179009 Background | Apr 2012 → Jun 2014 | mood disorder | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT01042093 Comparator | Jan 2010 → Jul 2011 | osteoarthritis, knee | Towson Orthopaedic Associates | Completed | No outcome recorded |
| — | NCT01015807 Comparator | Nov 2009 → Aug 2010 | secondary erythromelalgia | University of Washington | Completed | No outcome recorded |
| — | NCT00413582 Comparator | Oct 2006 → May 2010 | — | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| — | NCT00492973 Background | Mar 2006 → Feb 2008 | osteoarthritis, knee | New Lexington Clinic | Completed | No outcome recorded |
| — | NCT00226096 Background | Nov 2005 → Sep 2007 | intracerebral hemorrhage | The George Institute | Completed | No outcome recorded |
| — | NCT00638729 Comparator | Aug 2005 → Mar 2007 | anxiety | University Hospital Schleswig-Holstein | Completed | No outcome recorded |
| — | NCT00329511 Comparator | Sep 2004 → Dec 2008 | hypertensive disorder | Afshan B. Hameed, M.D. | Withdrawn | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 44 cited values
Every value below carries the sentence it was read from. 254 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clonidine | “Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane...” NCT03388814 ↗242“The "Treatment Arm" receive a single shot adductor canal block containing 20 milliliters (ml) of solution including 0.25% bupivacaine, 150 mcg of buprenorphine, 2 mg of...” NCT02991404 ↗ “Postoperative patient controlled epidural analgesia (epidural cathterer inserted into Th7-8 intervertebral space, 200 ml of 0.125% levobupivacaine, 4 mg of morphine, 0.075 mg...” NCT05831761 ↗ “A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the...” NCT02682498 ↗ “The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine...” NCT02026687 ↗ “In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium,...” NCT05485480 ↗ “Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)” NCT03342950 ↗ “The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block.” NCT04445337 ↗ “The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride” NCT04436250 ↗ “Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.” NCT03845894 ↗ “bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline” NCT00492973 ↗ “The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.” NCT04538573 ↗ “All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.” NCT02543944 ↗ “Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine” NCT02249039 ↗ “The study group (OFA group) will receive a combination of clonidine, magnesium sulfate, ketamine, and lidocaine.” PMID 34838109 ↗ Nov 2021 “Propranolol Versus Propranolol and Clonidine in Sympathetic Hyperactivity After Moderate Traumatic Brain Injury” NCT04833218 ↗ “15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.” NCT02128451 ↗ “The anesthetist prepares two sy-ringes with 20 ml each with ropivacaine 0.25% with 75 μg of clonidine.” NCT07377630 ↗ “2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection).” NCT05037812 ↗ “PCA pump with Ketamine, Lidocaine, Clonidine and Midazolam for the first 3 postoperative days.” NCT04894864 ↗ “Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1 mg/ml (0.08 mg = 0.8 ml)” NCT02571283 ↗ “Intrafascial injection of clonidine, epinephrine, ropivacaine, and toradol solution” NCT06935331 ↗ “20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine” NCT02741713 ↗ “In this group the investigators have given clonidine to the participants” NCT07297888 ↗ “PCA pump with Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam” NCT05172739 ↗ “Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)” NCT02371759 ↗ “Clonidine is a selective partial agonist of the alpha-2 receptors” NCT03121261 ↗ “PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone” NCT05676814 ↗ “Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl” NCT06781632 ↗ “prazosin, terazosin, clonidine, clonidine patch, methyldopa” NCT00684489 ↗ “Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex” NCT05916339 ↗ “fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg.” NCT00413582 ↗ “TCI propofol mixed with clonidine and ketamine” NCT05536362 ↗ “2% lidocaine + 1.5 mcg/kg clonidine” NCT01759524 ↗ “and 0.3 ml clonidine 150 µg ml-1” NCT02355678 ↗ “0.8 ml clonidine (0.1mg/ml)” NCT07151417 ↗ “Clonidine 100 mcg/mL, 0.4mL” NCT03696199 ↗ “Clonidine” NCT02628626 ↗ |
| Known as | ARC-4558 | “Drug: Clonidine Topical Gel (ARC-4558)” NCT00695565 ↗ |
| Known as | Catapres | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Catapres p.l. | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Catapres tts 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Catapres tts 2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Catapres TTS-3 | “Patients enrolled in the treatment group will receive an oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres...” NCT01139996 ↗ |
| Known as | Catapres, Kapvay (clonidine) | “Catapres, Kapvay (clonidine)” NCT05037812 ↗ |
| Known as | Catapres-TTS | “Transdermal clonidine (Catapres-TTS®) is a preparation of clonidine hydrochloride that can be released and absorbed transdermally over a 7-day period.” NCT00329511 ↗ |
| Known as | Catapresan | “The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine...” NCT02026687 ↗4“Clonidine was approved by the FDA in 1974 and is registered in Austria with the brand name "Catapresan".” NCT00279253 ↗ “Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml” NCT02466373 ↗ |
| Known as | Catapress | “Intervention Group: Start oral (PO/NG/OG) Clonidine HCl (Catapress) at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours depending on baby's feeding schedule.” NCT03092011 ↗ |
| Known as | Catapressan | “Currently, two pharmacological α-2 agonists, clonidine (Catapressan®, Boehringer Ingelheim) and dexmedetomidine (Dexdor®, Orion Corporation), are marketed and commonly used in...” NCT04758936 ↗ |
| Known as | Catarpres-tts | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | CLON | “The aim of this study was to determine the effect on family quality of life (QOL) of clonidine (CLON) and methylphenidate (MPH), used alone and in combination, in treating...” PMID 19877975 ↗ Oct 20092“Alpha 2-adrenergic receptor agonists, dexmedetomidine (DEX) and clonidine (CLON) have excellent sedative-analgesics effects, do not cause respiratory depression and are...” NCT02249039 ↗ “investigational study drug, Clonidine Hydrochloride ( CLON).” NCT01862250 ↗ |
| Known as | CLON-XR | “This study examined the efficacy and safety of clonidine hydrochloride extended-release tablets (CLON-XR) in children and adolescents with attention-deficit/hyperactivity...” PMID 21241954 ↗ Feb 2011 |
| Known as | CLONICEL | “CLONICEL (Clonidine HCl sustained release)” NCT00723190 ↗ |
| Known as | Clonidin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05318248 ↗ |
| Known as | Clonidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | clonidine [Catapres, Boehringer Ingelheim, Germany] | “clonidine [Catapres®, Boehringer Ingelheim, Germany]” NCT00860899 ↗ |
| Known as | Clonidine extended release | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Clonidine Gel | “Study CLO-311 is a multicenter, open-label, single-arm study to assess the long-term use of Clonidine Gel in the treatment of pain associated with PDN.” NCT02355158 ↗1“Clonidine Gel” NCT02643251 ↗ |
| Known as | Clonidine HCL | “Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.” NCT01360450 ↗5“Intervention Group: Start oral (PO/NG/OG) Clonidine HCl (Catapress) at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours depending on baby's feeding schedule.” NCT03092011 ↗ “Then, the drug test article, clonidine HCl, 0.1 mg tabs, will be administered once daily by mouth at bedtime for one week.” NCT04030572 ↗ “high dose clonidine HCl sustained release tablets for 8 weeks” NCT00556959 ↗ “Drug: Clonidine HCL” NCT07092566 ↗ “Drug: Clonidine HCL” NCT00510016 ↗ |
| Known as | Clonidine HCl sustained release | “CLONICEL (Clonidine HCl sustained release)” NCT00723190 ↗ |
| Known as | Clonidine Hydrochloride | “This study examined the efficacy and safety of clonidine hydrochloride extended-release tablets (CLON-XR) in children and adolescents with attention-deficit/hyperactivity...” PMID 21241954 ↗ Feb 20115“investigational study drug, Clonidine Hydrochloride ( CLON).” NCT01862250 ↗ “Clonidine Hydrochloride Topical Gel, 0.1%” NCT02643251 ↗ “Drug: Clonidine Hydrochloride” NCT02953210 ↗ |
| Known as | Clonidine hydrochloride component of clorpres | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Clonidine hydrochloride component of combipres | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Clonidine Lauriad | “Clonidine Lauriad® 50 μg and 100 μg Mucoadhesive Buccal Tablet (MBT)” NCT01385748 ↗ |
| Known as | Clorpres | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Combipres | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Dichloranilino imidazolin | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Dixarit | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Duraclon | “Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.” NCT01360450 ↗1“Clonidine (Duraclon®)” NCT01862250 ↗ |
| Known as | Jenloga | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Kapvay | “If Vyvanse +/- Adderall is also ineffective or not tolerated, participants will progress to Kapvay;” NCT04737512 ↗ |
| Known as | klonidin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02030717 ↗ |
| Known as | Nexiclon xr | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | NSC-756699 | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | Onyda xr | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | OnydaTM XR | “A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD” NCT07044609 ↗ |
| Known as | ST-155 | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Known as | ST-155-BS | ChEMBL registry synonym — accepted as the source's own label CHEMBL134 ↗ |
| Action | Activate | “It acts by stimulating adrenergic receptors on nerves in the brain and Imidazol-receptors.” NCT00279253 ↗ |
| Modality | Other / unclassified | “clonidine (an alpha-2 adrenergic agonist)” NCT02643355 ↗ |
| Route | Oral | “Clonidine 0.05-0.3 mg PO x 1 dose” NCT00262470 ↗ |